Top
image credit: Adobe Stock

FDA, citing safety concerns, places partial hold on Merck KGaA’s MS drug

April 12, 2023

Category:

Evobrutinib is part of a class of drugs known as BTK inhibitors, which target a protein called Bruton’s tyrosine kinase known to play a role in helping certain cancer cells proliferate. The FDA has approved four BTK inhibitors to treat blood cancers, with Lilly’s Jaypirca joining the mix in January. AbbVie and Johnson & Johnson’s Imbruvica is the market leader, pulling in net revenue of $4.6 billion last year.

Read More on Biopharma Dive